Insulin-like growth factor-II and insulin-like growth factor binding protein-2 prospectively predict longitudinal elevation of HDL-cholesterol in type 2 diabetes

• Published in: Annals of clinical biochemistry Vol. 51; no. Pt 4; p. 468
• Main Authors: Narayanan, Ram P, Fu, Bo, Oliver, Robert L, Siddals, Kirk W, Donn, Rachelle, Hudson, Julie E, White, Anne, Laing, Ian, Ollier, William E R, Heald, Adrian H, Gibson, J M
• Format: Journal Article
• Language: English
• Published: England 01.07.2014
• Subjects: Adult; Aged; Aged, 80 and over; Cholesterol, HDL - blood; Diabetes Mellitus, Type 2 - blood; Female; Humans; Insulin-Like Growth Factor Binding Protein 2 - blood; Insulin-Like Growth Factor II - metabolism; Longitudinal Studies; Male; Middle Aged; insulin-like growth factor binding protein-2; cholesterol; type 2 diabetes; Insulin-like growth factor-II; prospective; HDL-cholesterol
• ISSN: 1758-1001
• DOI: 10.1177/0004563213499145

Associations of insulin-like growth factor-II (IGF-II) and insulin-like growth factor binding protein-2 (IGFBP-2) with cardiovascular risk have been inadequately studied. We hypothesized that IGF-II and IGFBP-2 associate with longitudinal trends in lipid profiles in type 2 diabetes patients. Four hundred and eighty nine subjects with type 2 diabetes (age 27-87 years) from the Salford Diabetes Cohort were studied. Longitudinal clinical information was extracted for an eight-year period (2002-2009) from an integrated electronic dataset of primary care and hospital data. There were 294 male subjects and mean age was 62.9 years. At baseline, IGF-II concentration was 602 ng/mL. HDL cholesterol at baseline was associated with log-IGF-II concentration in a model adjusted for age, gender, baseline body-mass index (BMI), estimated glomerular filtration rate (eGFR) and lipid-lowering therapy. IGFBP-1 and IGFBP-2 were associated with high HDL-cholesterol. A higher circulating IGF-II concentration at baseline was also associated with longitudinal increase in HDL-cholesterol in mixed-effects regression analyses independent of IGF-I, IGFBP-1, IGFBP-2, IGFBP-3, age, gender, eGFR, BMI and lipid-lowering therapy. Log-transformed baseline concentrations of IGFBP-1 and IGFBP-2 were also associated with longitudinal elevation in HDL-cholesterol. No association was observed for IGF-II or IGFBP-2 with longitudinal LDL cholesterol trends. Our analyses based on 'real world' data demonstrate that higher baseline IGF-II and IGFBP-2 predict increased HDL concentration over time, implicating IGF-II in modulation of circulating HDL-cholesterol concentrations.